Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs


Department of Pharmacology and Experimental Neuroscience, College of Medicine, Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA. Center for Neural Development and Disease, University of Rochester Medical Center (URMC), Rochester, New York, USA.

Long-acting anti-HIV products can substantively change the standard of care for patients with HIV/AIDS. To this end, hydrophobic antiretroviral drugs (ARVs) were recently developed for parenteral administration at monthly or longer intervals. While shorter-acting hydrophilic drugs can be made into nanocarrier-encased prodrugs, the nanocarrier encasement must be boosted to establish long-acting ARV depots. The mixed-lineage kinase 3 (MLK-3) inhibitor URMC-099 provides this function by affecting autophagy. Here, we have shown that URMC-099 facilitates ARV sequestration and its antiretroviral responses by promoting the nuclear translocation of the transcription factor EB (TFEB). In monocyte-derived macrophages, URMC-099 induction of autophagy led to retention of nanoparticles containing the antiretroviral protease inhibitor atazanavir. These nanoparticles were localized within macrophage autophagosomes, leading to a 4-fold enhancement of mitochondrial and cell vitality. In rodents, URMC-099 activation of autophagy led to 50-fold increases in the plasma drug concentration of the viral integrase inhibitor dolutegravir. These data paralleled URMC-099–mediated induction of autophagy and the previously reported antiretroviral responses in HIV-1–infected humanized mice. We conclude that pharmacologic induction of autophagy provides a means to extend the action of a long-acting, slow, effective release of antiretroviral therapy.

Introduction

The next frontier for antiretroviral therapy (ART) rests in easing drug use, targeting viral reservoirs, extending drug half-life, reducing viral mutations, and overcoming systemic toxicity (1–3). We previously developed, characterized, and tested therapeutic responses of long-acting nanoformulated ART (nanoART) (4–11). Recent successes have come from encasing hydrophobic crystalline antiretroviral drugs (ARVs) into excipients, decorating the formed particles with ligands that target cells and tissue reservoirs or by pharmacologically boosting intracellular depot formations (4, 11–13). Such approaches extended the drugs’ half-life by controlling the rate of drug-particle dissociation and its release hydrolysis to the systemic circulation. However, the production of more hydrophobic and protein-bound ARVs provides only a partial solution. Controlling the dynamics of particle trafficking inside the cell and within early, recycling, and late endosomes is necessary to sustain intracellular drug particle depots and limit hepatic and renal metabolism and drug excretion (4, 6, 11, 14, 15).

We previously showed that nanoparticles of hydrophobic ARVs enscased in polymer excipients and coadministered with the mixed-lineage kinase 3 (MLK-3) inhibitor URMC-099 facilitated particle endocytic trafficking and enhanced intracellular drug retention (11). However, the mechanisms for how the MLK-3 inhibitor restricts viral growth were not known. Here, we demonstrate that URMC-099 enhancement of antiretroviral responses is due to the stimulation of autophagy and leads to the subsequent sequestration of drug particles into autophagosomes. An extension of the ARV half-life by URMC-099 was observed for atazanavir (ATV) and dolutegravir (DTG), viral protease and integrase inhibitors, respectively. An increased understanding of how nanoformulated ARV depots are maintained will facilitate the development of a spectrum of anti-HIV slow-release products and in turn enhance the effectiveness of clinical drug regimens. We believe that our work, in toto, represents a notable step forward in the development of sustained-release ARVs for human use.

Results

URMC-099 facilitates nanoART activity. We evaluated the ability of URMC-099 to affect the anti-HIV activity of nanoformulated ARVs in infected human monocyte-derived macrophages (MDMs). We treated HIV-1 ADA strain–infected (HIV-1ADA–infected) MDMs with 400 ng/ml URMC-099, followed by subtherapeutic concentrations (1 μM) of nanoformulated ATV (nanoATV) at 1, 3, and 5 days after infection at a multiplicity of 0.1 infectious virions per cell. The concentration of URMC-099 used elicited a maximal therapeutic efficacy that included drug particle retention, amloid β clearance, cellular vitality, and robust neuroprotective and antiinflammatory responses (11, 16–20). As concentrations of nanoATV of 100 μM or greater suppress viral replication, we performed URMC-099 dose-response determinations using subtherapeutic nanoATV concentrations for the measurement of viral growth. Progeny virion
formation in culture supernatant fluids was determined by reverse transcriptase (RT) activity. Notably, we found that URMC-099 administered with 1 μM nanoATV reduced virion production by 4-fold compared with virion production when nanoATV was given alone (Figure 1, A and B and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI90025DS1). In addition, coadministration of nanoATV and URMC-099 resulted in reductions of up to 4-fold in the numbers of HIV-1p24+ cells (Figure 1C). We found that the percentages of multinucleated giant cells (MNGCs) were also reduced with URMC-099 and nanoATV cotreatment on both days 1 and 3 after infection (Figure 1, D and E). In the presence of URMC-099, we observed mononucleated MDMs, whereas, without URMC-099, most of the cells were MNGCs by 14 days after infection (Figure 1E and Supplemental Figure 1B). On day 7 after infection, URMC-099 treatment alone showed a reduction in MNGCs compared with that observed with HIV-1 infection (Figure 1D); however, the effect was lost by day 14 (Figure 1E). On day 7 after infection, nanoART treatment initiated on day 3 after HIV-1 infection resulted in a greater number of MNGCs compared with those detected on day 1 of treatment initiation, and even this effect was lost by day 14 after infection.

**URMC-099 and mTORC1-dependent transcription factor EB nuclear translocation.** Since URMC-099 regulates JNK phosphorylation (18), we reasoned that URMC-099 would affect the mechanistic target of mTOR complex 1 (mTORC1) through JNK (21), which in turn would modulate vesicular trafficking through transcription factor EB (TFEB) (22). We found that URMC-099 could affect endosomial trafficking through any one or all of these factors (Supplemental Figure 2A). To understand the URMC-099 mechanism, we pretreated MDMs with 100 μM nanoATV, followed by HIV-1 infection and treatment with 400 ng/ml URMC-099. Here, we used the therapeutic level of 100 μM nanoATV to eliminate the virus-induced effect on signaling proteins and to differentiate the added outcome of URMC-099 from that of nanoATV alone. Moreover, a higher dose of nanoATV ensures the effect of URMC-099 on depot formation rather than on drug synergy (between ATV and URMC-099). URMC-099 was administered throughout the experimental period, while nanoATV was administered only once at the start of the experiment. After 14 days, TFEB levels were quantified in the cytoplasmic and nuclear fractions by Western blot analysis. With URMC-099 treatment, TFEB levels were increased by 2- to 3-fold in the nuclear cell fraction and reduced by 2-fold in the cytoplasmic fraction when compared with the levels detected with nanoATV treatment alone (Figure 2, A and B). Since the inhibition of JNK phosphorylation negatively regulates mTORC1, we tested whether URMC-099 could inhibit mTORC1 function. Ser2448 phosphorylation of the kinase mTORC1 regulates nuclear translocation of TFEB (23, 24). We observed that URMC-099 treatment increased Ser2448 phosphorylation by 2.2 ± 0.51-fold (Figure 2, A and C). HIV-1 sequesters TFEB in the cytoplasm through HIV-1 Nef (25), and we observed sequestration of TFEB in the cytoplasmic fraction following viral infection. This was reversed by URMC-099 within HIV-1-infected MDMs and MNGCs (Figure 2, A, B and D). URMC-099 treatment led to 80% localization of TFEB in the nuclei of MDMs compared with only 20% localization without URMC-099 treatment (Figure 2, D and E). URMC-099 also triggered increases in the transcription of TFEB mRNA by approximately 4- to 8-fold under different treatment conditions (Figure 2F). With HIV-1 infection, TFEB mRNA levels were reduced by 2- to 3-fold compared with levels in uninfected controls, and URMC-099 could recover the phenotype. Increased TFEB translocation was delayed and did not reach significant levels until day 7 after URMC-099 treatment (Supplemental Figure 2B). These data confirm that URMC-099 regulates TFEB nuclear translocation in an mTORC1-dependent manner.

**URMC-099 stimulates autophagy in human MDMs.** On the basis of the preceding data sets, we theorized that nuclear translocation of TFEB induces autophagy and lysosomal biogenesis. TFEB serves as the master regulator of both autophagy and lysosomal biogenesis (26), and such regulation could have a profound role in nanoART intracellular sequestration in MDMs. Thus, we examined the autophagosome markers microtubule-associated protein 1 light chain 3 β (LC3B, also known as MAP1LC3B) and beclin 1 (BECN1). Using Western blot assays, we found that each marker was significantly upregulated by URMC-099 (Figure 3, A–C and Supplemental Figure 3A). URMC-099 increased the expression of both LC3B1 and LC3BII from day 7 onward (Supplemental Figure 3A). Significant increases in LC3BII/LC3B1 ratios were induced by URMC-099 (Figure 3B) and support autophagosome formation. These data support the finding of TFEB nuclear localization and confirm that autophagy is induced through TFEB. Degradation of sequestosome 1 (SQSTM1), a marker of autophagosome sequestration, was subsequently investigated for its role in autophagosome-lysosome fusion, which is known to occur during the completion of autophagy (27). Interestingly, URMC-099 did not induce significant increases in SQSTM1 levels compared with those in controls (Figure 3, A and C and Supplemental Figure 3A). Furthermore, while increases in LC3B (MAP1LC3B), BECN1, and SQSTM1 gene expression were detected with URMC-099 treatment (Figure 3D and Supplemental Figure 3B), these increases affected only LC3B and BECN1, but not SQSTM1, protein expression (Figure 3C and Supplemental Figure 3A). The results imply that autophagosomes are increased as a consequence of URMC-099 treatment and fuse with lysosomes, but that a delayed response is operational (Supplemental Figure 3A). TFEB nuclear translocation leads to increases in TFEB mRNA levels and the induction of autophagy (28, 29). This likely represents the lack of any distinctive differences in autophagy-specific proteins among URMC-099–treated groups, irrespective of HIV-1 infection or nanoATV. HIV-1 differentially regulates autophagy at early and later stages of viral infection (25). Fourteen days after infection of MDMs, we found that HIV-1 inhibited autophagy, as indicated by decreased levels of LC3B and BECN1, whereas SQSTM1 levels were increased following HIV-1 infection. These findings were independent of URMC-099 treatments and are linked, in measure, to the known inhibition of autophagy by HIV-1 and transcriptional activation of SQSTM1 by URMC-099. Importantly, URMC-099 reversed HIV-1–induced downregulation of autophagy during the later stages of viral infection of MDMs (Figure 3, A, C and D).

**URMC-099 improves mitochondrial activity and cell vitality.** Autophagy is a known mechanism for mitochondrial turnover (30), and increased autophagy leads to increased cell viability (31). In order to better understand the relationships between autophagy and cellular recycling processes, we measured cellular metabolic activity by the MTT assay, which is an index of tetrazolium dye reduction due to NAD(P)H-dependent oxidoreductase activity.
Figure 1. URMC-099 potentiates antiretroviral activity of ARV nanoformulations. HIV-1ΔG2-infected human MDMs were treated with 1 μM nanoATV on (A) day 1 or (B) day 3 after infection in the presence or absence of 400 ng/ml URMC-099. Supernatants were collected on different days after infection to measure HIV-1 RT activity. Values represent the mean ± SD (n = 5). The same HIV control plot is presented in A and B. For a better comparison, see the HIV control plot in Figure 5, A and B, and in Supplemental Figure 5, A, B, E, and F. The mean was compared by 2-way ANOVA, which showed a time-dependent effect (P < 0.0001). Pairwise comparisons were performed with Bonferroni’s post-hoc test for P < 0.05 compared with ‘control, *NanoATV, and ‘URMC-099.

(C) On day 7 after infection, the cells were fixed and stained for HIV-1 p24 antigen and counterstained with hematoxylin. Multi- and mononucleated cells are marked with white and black arrowheads, respectively. Scale bar: 20 μm. On (D) day 7 and (E) day 14 after infection, the percentage of MNGCs was quantified from the total number of cells in 20 different fields. Values represent the mean ± SD. **P ≤ 0.01 and ***P ≤ 0.001, by Student’s t test. Multiple comparisons were corrected for the FDR by the Benjamini-Hochberg method, and data are representative of 3 independent experiments. dpi, days post infection.
and thus can be used to assess mitochondrial health. MTT activity was determined in infected and uninfected MDMs with or without URMC-099 and/or nanoATV treatment. Our findings showed significant and specific increases in MTT activity as the sole result of URMC-099 treatment (Figure 3E and Supplemental Figure 3C). With similar treatments, a trypan blue exclusion assay showed no difference in cell viability with URMC-099 alone (Supplemental Figure 3, D and E). Though there was no change in cell viability with URMC-099 treatment, we observed increased mitochondrial activity. However, HIV-1 infection led to cytotoxicity in macrophages and yielded reduced cell viability compared with what we observed in uninfected controls (Supplemental Figure 3D).

**URMC-099 retains ARV nanoparticles in autophagosomes.** We next reasoned that autophagy facilitated by URMC-099 might affect the retention of nanoATV that we observed previously (II). This was studied by treating uninfected or HIV-1–infected MDMs with 10 μM CF633–labeled nanoATV. Cells were also cultured in the presence or absence of URMC-099 for 12 days and then transfected with a GFP-tagged LC3B construct (LC3B-GFP). We observed increased numbers of LC3B puncta and localization of nanoATV in LC3B+ autophagosomes in the presence of URMC-099 (Figure 4, A and B). In addition, we detected increased nanoATV fluorescent signals from URMC-099–treated cells compared with untreated control cells. Inhibition of autophagy by 3-methyladenine (3-MA) decreased autophagosome numbers and nanoATV fluorescent signals (Figure 4, A and B). To confirm these observations, ATV levels were quantified in total cell lysates and autophagosomes. For the latter, LC3B+ autophagosomes were isolated by magnetic bead pull-down (32), and ATV levels were measured by HPLC. Drug levels increased by 1.5- to 2.5-fold in both cells and autophagosomes as a consequence of URMC-099 treatment when compared with levels detected in the untreated cells (Figure 4C). The use of TFEB or autophagy-related 13 (ATG13) siRNA demonstrated a reversal of URMC-099–induced cellular drug retention (Figure 4D). These findings confirmed that URMC-099 induces macrophage drug depots and that these effects are mediated through TFEB and the formation of autophagosomes. The process, notably, requires ATG13 (33). Although nanoATV was localized in compartments of Rab–related proteins 7 and 11 (Rab7 and Rab11), regardless of URMC-099 treatment (11), the subcellular fate of nanoATV in Rab compartments, fused with autophagosomes, or rather in phagosomes at different stages of maturation, remained unclear. URMC-099 treatment increased the colocalization of LC3B and endosomal Rab proteins (Rab7 and Rab11) (Supplemental Figure 4, A and B), suggesting that fusion occurred between endosomes and autophagosomes (34–36). Although there were no differences in the uptake of nanoATV in URMC-099–treated MDMs (11), the increased retention of nanoATV by URMC-099 reduced the release kinetics of nanoATV, resulting in a sustained, slower release of the drug (Figure 4E). Together, these data suggest that induction of autophagy leads to increased retention of nanoATV and a sustained slow release of drug.

**Autophagy facilitates nanoformulated ARV activity.** It is well accepted that autophagosomes are used for HIV-1 assembly and maturation (25, 39, 40). Thus, we investigated whether autophagy could affect HIV-1 replication in MDMs in the setting of nanoATV treatment. In these experiments, MDMs were treated with a subtherapeutic dose of 1 μM nanoATV at 1 or 3 days after HIV-1 infection, with or without URMC-099 cotreatment. When autophagy was inhibited in the initial stage of regulation with the PI3K inhibitors 3-MA or wortmannin, the viral-suppressive effect of URMC-099 shown in Figure 1, A and B, was reversed (Figure 5A and Supplemental Figure 5A). We used these PI3K inhibitors, since PI3K is upstream of mTOR signaling and is required for autophagy. JNK pathway crosstalk with PI3K-mediated mTOR signaling is not directly involved in mTOR regulation (41). Thus, inhibiting PI3K signaling affects autophagy independently of URMC-099, and these PI3K inhibitors revealed the involvement of autophagy in URMC-099–enhanced ARV activity. Inhibition with chloroquine or bafilomycin A1 in the later stages of autophagy that include autophagosome-lysosome fusion did not alter the URMC-099 effect (Figure 5B and Supplemental Figure 5B). However, the URMC-099–induced increase in MTT activity in MDMs was reduced with either 3-MA or chloroquine, independently of HIV-1 infection (Supplemental Figure 5C). These data indicate that autophagosome accumulation is required to facilitate maximal nanoATV effectiveness but that autophagosome-lysosome fusion is required for autophagy-induced mitochondrial activity. We observed a similar reduction in HIV-1 infection when rapamycin, an mTOR inhibitor and a known autophagy inducer, was used with 1 μM nanoATV (Supplemental Figure 5D). The rapamycin effect was lost with the autophagy inhibitor 3-MA, but not with chloroquine (Supplemental Figure 5, E and F). Taking into account the action of ATV as an HIV-1 protease inhibitor and the autophagosome involvement in HIV-1 biogenesis, we posit that drug and virus interactions enhanced by URMC-099 could be the reasons for further attenuation of HIV-1 infection.

To investigate autophagosome-lysosome fusion, we treated MDMs with the protein synthesis inhibitor cycloheximide after the cells were exposed to URMC-099. During this fusion, LC3B is lipoadated to LC3II and released into the cytoplasm. While increases in both LC3BII and LC3BI were affected by URMC-099, LC3BI was decreased by cycloheximide on day 7 (Supplemental Figure 6, A–C) and day 14 (Figure 5, C–E). Since URMC-099 induces autophagy transcriptionally, new autophagosomes were synthesized continuously, hence the increase we observed in the levels of both LC3BII and LC3BI. When translation was inhibited by cycloheximide, the existing autophagosomes fused with lyso-
somes, resulting in a reduction of LC3BI levels (Figure 5, C and D). Induction of LC3B with URMC-099 treatment was reversed by treatment with TFEB siRNA, but not with ATG13 siRNA (Figure 5F). Confocal imaging also showed a reduction of LC3B expression with TFEB silencing (Supplemental Figure 6D). This further confirms that TFEB is required for autophagy induction and that URMC-099 acts through TFEB. Since ATG13 is involved in autophagosome formation, ATG13 did not have an impact on the effects of URMC-099 on LC3B or BECN1 expression (Figure 5F), whereas nanoATV retention in the autophagosomes was affected by ATG13 silencing (Figure 4D).

LC3B-positive autophagosomes were also colocalized with lysosomal-associated membrane protein 1 (LAMP1), confirming fusion of autophagosomes with lysosomes (Figure 5G). To further confirm autophagosome-lysosome fusion, we quantified IL-1β levels, as fusion leads to IL-1β degradation and reduced
secretion (42). IL-1β levels were quantified by ELISA and a cytokine bead array under different treatment conditions. We confirmed by ELISA that URMC-099 decreased IL-1β secretion by 4.4 ± 0.9-fold (Supplemental Figure 7A) and by 4.2-fold with a cytokine bead array (Supplemental Figure 7B).

Stimulation of autophagy in animals given URMC-099. To understand the effect of URMC-099 in vivo, mice were treated with twice-daily i.p. injections of 10 mg/kg URMC-099. A plasma concentration of approximately 1,000 ng/ml (2 μM) was achieved with this treatment (Supplemental Figure 8A). We found that URMC-099 had no adverse effect on the body weight of the mice (Supplemental Figure 8B). As TFEB induces autophagy in tissue (26, 43, 44), we tested whether URMC-099 treatment leads to activation of autophagy in spleen and liver. Real-time quantitative PCR (qPCR) showed an upregulation of Tfeb, Maplc3b, Becn1, and Sqstm1 levels in the livers of URMC-099–treated mice (Figure 6A). Similarly, LC3B, BECN1, and SQSTM1 protein expression levels were also increased when mice were treated with URMC-099 (Figure 6, B–D). These data match those from previous studies showing that upregulation of Tfeb triggers a transcriptional activation of autophagy–linked genes (26). Additionally, immunohistochemical staining of splenic tissue sections showed increased LC3B expression in URMC-099–treated mice (Figure 6E), which further evidenced autophagy induction by URMC-099. In URMC-099–treated mice, we observed increased numbers of LC3B puncta in CD68+ mouse splenic macrophages (Figure 6F).

To further elucidate the effect of URMC-099 on HIV-1 infection in vivo, we examined humanized NOD/SCID IL-2rg−/− (NSG) mice infected with HIV-1 and treated with URMC-099. We found that URMC-099 alone did not affect the plasma HIV levels (Figure 7A). It is known that acute and chronic HIV-1 infection leads to increased IL-1β secretion in vitro and in vivo (45, 46). URMC-099 treatment in our study reduced plasma IL-1β concentrations compared with the plasma concentrations in HIV-1–infected controls (Figure 7B). In URMC-099–treated humanized mice, LC3B puncta in CD68+ macrophages were also readily apparent (Figure 7C). These results suggest that URMC-099 modulates HIV-1–induced cytokine responses in vivo through autophagy (6, 47).

Improved pharmacokinetic profiles of nanoformulated ARVs with URMC-099 treatment. We used the HIV-1 integrase inhibitor DTG to understand the role of autophagy and nanoARV in vivo. Mice injected with a single i.m. dose (45 mg/kg) of nanoformulated DTG (nanoDTG), with or without daily i.p. injections of 10 mg/kg URMC-099, showed no adverse effects on their body weight or health (Supplemental Figure 9A). We observed increased plasma DTG levels in URMC-099–treated mice beginning on day 14, and by day 28, there was a 52.3 ± 5.7-fold increase in the plasma drug level compared with levels detected in animals treated with nanoDTG alone (Figure 8A). Similar increases in DTG levels in spleen, liver, and lymph nodes were achieved with URMC-099 treatment (Figure 8B). At early time points, i.e., on days 1 and 3 after nanoDTG administration, we found that the drug levels in both plasma and tissues were not significantly increased with URMC-099, and the autophagy proteins were also not affected with URMC-099 treatment at these time points, suggesting a delayed response (Supplemental Figure 9, B and C).

Real-time qPCR of spleen and liver tissues showed a significant increase in Tfeb levels in URMC-099–treated mice, which in turn promoted higher expression of the autophagy genes Maplc3b, Becn1, and Sqstm1 (Figure 8, C–F). Western blot analyses confirmed a parallel induction of autophagy proteins in spleen and liver by days 14 and 28 of URMC-099 treatment (Figure 8, G and H, and Supplemental Figure 10, A–E). Together, these results show that autophagy induction by URMC-099 enhances nanoARV half-life in vivo.

Discussion

There is an immediate need for long-acting ART in order to meet the challenges of HIV/AIDS regimen adherence. Notably, the secondary gains we achieved in the present study through reductions in drug dosages and improved viral reservoir penetration may prove to be even more significant in the era of viral eradication. The ability to facilitate drug depots and enhance vesicular trafficking of ARV nanoparticles and their sequestration in endosomal compartments is of significance for achieving long-acting ART. We believe that the development of adjunctive drugs such as URMC-099, designed to extend ART action by harnessing a natural cellular process such as autophagy and thereby facilitate drug depots, represents a novel approach to this challenge. The links between TFEB, a master regulator of autophagy, and ARV nanoparticle cellular trafficking by URMC-099 provide a critical new pathway for sustaining antiretroviral activity.

This study is based on our earlier work showing that reductions in viral replication and cytopathicity are due to retention of nanoARVs in Rab compartments by URMC-099 (11). On the basis of the presumptive interactions between endosomal trafficking, cytoskeletal rearrangement, and Rab proteins, we began to explore known pathways that affect cellular trafficking to elucidate the underlying mechanism. Prior associations of URMC-099 with the phosphorylation of p54 and p46 JNK isoforms in HIV-Tat–treated BV-2 microglial cells provided mechanistic clues (48). However, while autophagy is a well-accepted cellular process involved in the recycling of cytoplasmic organelles, macromolecules, and other defective proteins (27), its role in establishing the types of drug depots and sequestration of drug-laden nanoparticles is far from proven. During steady-state conditions, autophagy is maintained at low levels but can be affected by stress, organelle damage, or microbial infections (49, 50). It is also well known that chronic HIV-1 infection inhibits autophagy (51), while its induction inhibits infection (25, 40, 52). Thus, linkages between viral infection, autophagy, and nanoparticle sequestration could be reasoned and were also supported by previous reports involving a range of experimental systems (53, 54).

URMC-099 treatment was shown here, for the first time to our knowledge, to induce autophagy and enhance anti-HIV activities by sustaining depots of nanoformulated ARVs. The puzzle pieces came together, buoyed by a number of observations. First, URMC-099 activated autophagy through nuclear translocation of TFEB. Second, increased autophagy resulted in an increase in both the number of ARV nanoparticles in autophagosomes and ART half-life. Third, by altering HIV-1–regulated autophagy, we observed a suppression of viral replication.

The relationships that we observed in this study among HIV-1, macrophages, URMC-099, TFEB, lysosomal biogenesis, and autophagy are noteworthy. The importance of monocyte–macrophages as viral reservoirs, vehicles for microbial dissemination, secretors
of bioactive factors, and clearance vehicles for tissue metabolism and infectious materials cannot be overstated (28, 55). Such seemingly complicated intracellular events can, paradoxically, sustain HIV-1 growth by sequestering cytoplasmic TFEB through HIV-1 Nef and inhibiting autophagy (25). Nevertheless, URMC-099 overcame these HIV-1 effects by transcriptional control of Nef and inhibiting autophagy (25). Nevertheless, URMC-099 activation of autophagy can overcome HIV-1–induced IL-1β protein synthesis was inhibited. In addition, HIV-1 induces IL-1β production (25), whereby HIV-1 inhibits autophagosome maturation to evade its own destruction by lysosomal degradation (52). URMC-099 activation of autophagy can overcome HIV-1–mediated inhibition of autophagy. Thus, a dual antiretroviral response is seen: one through intracellular degradation of virus and the other through sustainment of ARV particles that preclude new infections.

To elucidate whether autophagy could affect nanoART–mediated restriction of viral replication, we examined autophago-some-lysosome fusion events affected by URMC-099. Reduced and increased levels of LC3B1 and LC3BII, respectively, confirmed that fusion of autophagosomes with lysosomes occurred when protein synthesis was inhibited. In addition, HIV-1 induces IL-1β macrophage secretion through TLR8 (57), and autophagy controls IL-1β cytokine levels. This occurs by sequestering the cytokine in autophagosomes and degrading it via lysosome fusion through autophagy-related 16-like 1 (ATG16L1) (42, 58). This process is likely important, as degradation of HIV-1–induced IL-1β is closely linked to autophagosome–lysosome fusion and HIV-1 clearance (42). It is certainly possible that autophagosome–lysosome fusion events recycle as a consequence of URMC-099 treatment and lead to further HIV-1 restriction.

URMC-099 affects cytoskeletal rearrangement and improves macrophage vitality by increasing mitochondrial activity. Indeed, combinations of URMC-099 and ATV nanoparticles resulted in reduced formation of MNGCs. This was readily apparent by days 7 and 14 after viral infection. Indeed, HIV-1–associated MNGCs alter the cellular cytoskeleton (59), and such protein rearrangements are autophagy regulated (14, 60). Thus, both processes are affected by nanoART and URMC-099. Indeed, the combination of nanoATV and URMC-099 attenuates giant cell formation, most likely by affecting endosomal and vesicular trafficking and reducing cytoskeletal rearrangements (61). These data support the notion that URMC-099 induces the changes in endosomal trafficking that affect known intracellular ARV particle accumulation (11). Macrophages play a key role in HIV-1 pathogenesis by forming viral reservoirs and selectively clearing HIV-1–infected CD4+ T lymphocytes (62, 63). As nanoART is also taken up by macrophages, increased retention, sustained release, and improved cellular viability by activation of autophagy can facilitate anti-HIV treatment outcomes. Given that our animal studies demonstrate that autophagy is induced in tissue macrophages and that combinations of nanoDTG and URMC-099 improve pharmacokinetic (PK) profiles, such treatment combinations could serve to further reduce HIV disease morbidities. In summary, we have shown that induction of autophagy leads to the retention and sustained release of nanoformulated ARVs. Our results, for the first time to our knowledge, lend credence to the idea that induction of autophagy by URMC-099 treatment activates a unique pathway that facilitates the biodistribution and half-life of long-acting nanoART. Possible mechanisms leading to a prolonged half-life of nanoART by URMC-099 are illustrated in Figure 9. As autophagosomes intersect with the HIV-1 life cycle, storage of the nanoformulated ARVs in intracellular compartments may further facilitate HIV-1 disposal by harnessing intracellular events that contain viral growth. Moreover, the effect of URMC-099 on TFEB nuclear localization and its outcome on autophagy could have other beneficial effects in combating a range of degenerative disorders that include, but are not limited to, Batten disease, Pompe disease, Gaucher disease, cystinosis, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease. TFEB is used as a therapeutic target in the treatment of these diseases (64).

In conclusion, we demonstrate in the present study that URMC-099 has the potential to reduce the dosage and frequency of ARV administration and enhance antiretroviral activity and believe that the development of this and similar sustained-release agents would be effective additions to the existing arsenal of anti-HIV drugs.

Methods
Preparation of nanoformulated antiretroviral drugs. Nanoformulations of ATV and DTG were prepared by high-pressure homogenization (Avestin EmulsiFlex-C3; Avestin Inc.) (10, 65) (See the Supplemental Experimen-
Figure 5. URMC-099-induced autophagy affects HIV-1 clearance. HIV-1<sub>ADA</sub>-infected human MDMs were treated with 1 μM nanoATV on day 1 or day 3 after infection and incubated with or without 400 ng/ml URMC-099 and in the presence of the autophagy inhibitors (A) 3-MA (100 μM) or (B) chloroquine (10 μM). Supernatants were collected on different days after infection and analyzed for HIV-1 RT activity (n = 5). The same HIV-1 infection control plot is presented in A and B. (A and B) The mean values of RT activity were assessed by 2-way factorial ANOVA, which showed a significant time-dependent treatment effect (*P < 0.02). Pairwise comparisons using Bonferroni’s post-hoc test were assessed for URMC-099–treated cultures, with P < 0.05 compared with UV-infected controls in the absence (‘control’) or presence (‘HIV’) of an autophagy inhibitor. (C–E) MDMs were treated in the presence or absence of 400 ng/ml URMC-099 for 14 days. Twenty-four hours or twelve hours before harvesting, cells were treated with 10 μM cycloheximide (CHX) to inhibit translation. Total cell lysates were analyzed by Western blotting. (D) Values represent the mean ± SEM of LC3Bl/LC3B ratios and were compared by Student’s t test and adjusted for multiple comparisons using the Benjamini-Hochberg method. *P ≤ 0.05 and **P ≤ 0.01 (n = 3). (E) Differences in mean fold changes were assessed by 2-way ANOVA and pairwise comparisons with the respective proteins was done using Bonferroni’s post-hoc test. P ≤ 0.05 for ‘no URMC-099/no CHX control’ and ‘URMC-099/no CHX control (n = 3). (F) Human MDMs treated with 400 ng/ml URMC-099 were transfected with either TFEB siRNA or ATG13 siRNA on days 3 and 7. On day 14, cell lysates were analyzed by Western blotting. (G) URMC-099–treated (400 ng/ml) and untreated (control) MDMs were transfected with LC3B-GFP on day 12, and 48 hours later were stained and imaged with a confocal microscope. Scale bars: 20 μm. Data are representative of 3 independent experiments.

**Human monocytic macrophages**. Human monocytes were isolated by leukapheresis from HIV-1/2 and hepatitis seronegative donors. Cells were cultured in DMEM (Invitrogen, Thermo Fisher Scientific) enriched with 10% heat-inactivated, pooled human serum, 2 mM L-glutamine, 50 μg/ml gentamicin, 10 μg/ml ciprofloxacin, and macrophage colony-stimulating factor (MCSF, collected as supernatants from ATCC 10154) conditioned medium. Cells were maintained at 37°C in a 5% CO<sub>2</sub> incubator (66).

**HIV-1 infection and drug treatments**. MDMs were infected with the HIV-1 ADA strain at an MOI of 0.01. URMC-099 dissolved in DMSO was used for all in vitro experiments. For pretreatments, MDMs were treated with 1, 10, or 100 μM nanoATV for 16 hours, then washed with PBS and infected with HIV-1<sub>ADA</sub> for 4 hours. After infection, cells were incubated with or without 100 or 400 ng/ml (237 or 950 nM) URMC-099 for an additional 14 days. For the post-treatment procedure, MDMs were infected and then treated with nanoATV on days 1, 3, and 5 after HIV-1 infection. MDMs were incubated with 400 ng/ml URMC-099 throughout the experimental time period. MDMs were treated with the autophagy inhibitors 3-MA (100 μM), wortmannin (50 nM), chloroquine (10 μM), or bafilomycin A1 (200 nM), or the known autophagy inducer rapamycin (20 nM). Cycloheximide (10 μM) was added to the cells 12 hours and 24 hours before terminating the experiments on day 7 or 14 to inhibit new protein synthesis.

**HIV-1 p24 antigen staining and RT activity assay**. For HIV-1p24 staining, MDMs were fixed with 4% ice-cold paraformaldehyde (PFA) in PBS for 20 minutes. Fixed cells were washed with PBS and permeabilized with 0.5% Triton X-100 in PBS for 15 minutes at room temperature. Cells were blocked using 10% goat serum in PBS for 30 minutes and incubated with mouse mAb against HIV-1p24. The polymer-based HRP-conjugated anti-mouse Dako EnVision system was used as a secondary detection reagent, and DAB (Dako) was used as chromogen. Images were captured with ×63 and ×20 objectives using a Nuance EX multispectral imaging system fixed to a Nikon Eclipse E800 microscope (Nikon Instruments). HIV-1 RT activity was measured as previously described (67). See the Supplemental Experimental Procedures for further details.

**Cytokine and autophagy pathway measurements**. IL-1β from MDM culture supernatants or plasma was quantified using an IL-1β ELISA Kit (eBioscience, Affymetrix). Briefly, samples were incubated on a capture antibody–coated 96-well plate overnight at 4°C after blocking with an ELISPOT diluent. Detection antibody and avidin-HRP were added sequentially, followed by 5 washes. Next, 3,3',5,5'-tetramethylbenzidine (TMB) solution and stop solution were added to stop the reaction. IL-1β levels were quantified spectrophotometrically by measuring absorbance at 450 nm. A bead-based cytokine array assay (BD Biosciences) was performed on MDM culture supernatants according to the manufacturer’s instructions. Autophagy gene expression was analyzed using real-time qPCR. RNA was isolated from cells or tissues using TRIzol (Applied Biosystems, Thermo Fisher Scientific) as per the manufacturer’s protocol. Residual DNA was removed using the TURBO DNA-Free Kit (Thermo Fisher Scientific). The isolated RNA (2 μg) was reverse transcribed to cDNA using a Verso Reverse Transcription cDNA Synthesis Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. TaqMan probes (Thermo Fisher Scientific) (Supplemental Table 1) and Real-time PCR Master Mix (Applied Biosystems) were used for real-time qPCR (StepOne Plus; Applied Biosystems) according to the manufacturer’s instructions. All samples were amplified in triplicate, and data were normalized to GAPDH or actin cDNAs.

**Silencing TFEB and ATG13 expression**. Human MDMs were incubated with or without 400 ng/ml URMC-099. On day 3 after URMC-099 treatment, MDMs were treated with either 10 μM TFEB or ATG13 siRNA (Ambion, Thermo Fisher Scientific) lipid complexes. siRNA was diluted in Opti-MEM medium (Life Technologies, Thermo Fisher Scientific), and lipid complexes were formed by incubating diluted siRNA in Lipofectamine RNAiMAX Reagent (Invitrogen, Thermo Fisher Scientific). Cells were treated with siRNA for 24 hours. A similar siRNA treatment procedure was followed on day 7. On day 12, MDMs were transfected with LC3B-GFP for confocal microscopy. Another set of MDMs treated similarly with siRNAs were lyzed for Western blot analyses to detect LC3B and for drug measurements.

**Confocal microscopy**. Human MDMs after treatment and infection were fixed in 4% PFA for 15 minutes, permeabilized in 0.5% Triton X-100 for 5 minutes, and blocked for 1 hour in 5% BSA solution. MDMs were incubated with anti-TFEB antibody overnight at 4°C, followed by incubation with Alexa Fluor 594–conjugated secondary antibody (Thermo Fisher Scientific). ProLong Gold anti-fade reagent with 2-(4-aminophenyl)-1H-indole-6-carboxamide (Thermo Fisher Scientific) (27) was used to mount the coverslip. Human MDMs were pretreated with 10 μM CF633-labeled nanoATV for 16 hours, infected with HIV-1<sub>ADA</sub> washed 3 times with PBS, and incubated with or without 400 ng/ml URMC-099 for 14 days in the presence or absence of the autophagy inhibitor 3-MA. On day 12, MDMs were transfected
Autophagosome isolation and drug quantification. MDMs were treated with 10 or 100 μM nanoATV for 16 hours, washed thrice with PBS, and then treated with or without 400 ng/ml URMC-099 for 14 days. Subsequently, ATV concentrations in total cells or LC3B-positive autophagosomal compartments were determined. LC3B-positive compartments were immunoisolated using LC3B antibody as described elsewhere (6, 56). See the Supplemental Experimental Procedures for additional details.
URMC-099 treatment in mice. In parallel experiments designed to assess URMC-099-induced autophagy in vivo, male BALB/cj mice (The Jackson Laboratory) were maintained on a normal diet with free access to food and water throughout the study. Mice were treated with i.p. injections of 10 mg/kg URMC-099 or equivalent vehicle dosage [poly(ethylene glycol)400/DMSO (8:1) mixture]. Plasma was collected 10 weeks after infection, and IL-1β levels were quantified. Viral load in the blood was measured using an automated COBAS AmpliCope System V1.5 (Roche Molecular Diagnostics). Mouse plasma (20 μl) was diluted with 480 μl of sterile normal human plasma for the assay. The baseline detection of the assay after dilution was 1,250 viral RNA copies per milliliter.

PK evaluations. Male BALB/cj mice were injected i.m. with 45 mg/kg nanoDTG, with or without daily i.p. injections of 10 mg/kg URMC-099 or equivalent vehicle dosage [poly(ethylene glycol)400/DMSO (8:1) mixture]. Plasma was collected 1, 3, 7, 14, 21, and 28 days after nanoDTG treatment. Animals were sacrificed, and tissues (liver, spleen, and lymph nodes) were collected on days 14 and 28. DTG levels in plasma and tissues were determined by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) (see the Supplemental Experimental Procedures for additional details).

Immunohistology. Spleens and livers were fixed in 4% PFA overnight. Paraffin-embedded, 5-μm-thick sections were stained with LC3B antibodies. An HRP-conjugated secondary antibody against rabbit IgG was added and developed with 3,3′-diaminobenzidine. Images were captured using ×20 and ×40 objectives. For immunofluorescence staining, sections were stained using antibodies against mouse CD68 and LC3B (green) in macrophages. DAPI was used to stain nuclei. The merged panel shows colocalization of LC3B and CD68 in spleens from URMC-099-treated mice. Scale bars: 20 μm.

ATV concentration in total cells and in the isolated compartments was quantitated by HPLC as previously described (6, 56).

Figure 7. URMC-099 treatment in humanized mice. (A and B) Humanized NSG mice were infected with HIV-1<sub>ADA</sub> and treated with URMC-099 (n = 4 per group). Ten weeks after infection, (A) plasma viral load and (B) plasma IL-1β concentration were determined (n = 4 mice per group). Values represent the mean ± SEM. ***P ≤ 0.001, by Mann-Whitney U test. (C) Paraffin-embedded spleen tissue sections from URMC-099-treated and control HIV-1–infected humanized mice were stained for LC3B (red) in autophagosomes and CD68 (green) in macrophages. DAPI was used to stain nuclei. The merged panel shows colocalization of LC3B and CD68 in spleens from URMC-099-treated mice. Scale bars: 20 μm.
Figure 8. URMC-099 and nanoART parenteral coadministration sustains plasma DTG levels. Mice were injected i.m. with a single dose (45 mg/kg) of nanoDTG and treated with or without daily i.p. injections of URMC-099 (10 mg/kg). (A) On different days, blood was collected, and the plasma DTG concentration was determined by UPLC-MS/MS. (B) On day 14 (D14) and day 28 (D28), mice were sacrificed and DTG levels quantified in different tissues by UPLC-MS/MS. (C–F) On days 14 and 28, total RNA was isolated from splenic and liver tissues, and real-time qPCR was performed for different genes. Values represent the mean ± SEM. *P ≤ 0.05 and **P ≤ 0.01, by Mann-Whitney U test (n = 6 mice per group). (G and H) On days 14 and 28, splenic and liver tissues were collected, and total tissue lysate was analyzed by Western blotting for different autophagy markers. Each lane is representative of 5 animals from each of the groups. Multiple comparisons were corrected for the FDR using the Benjamini-Hochberg method. Six mice were assessed per group.
Study approval. All animal studies were performed in compliance with UNMC institutional policies and NIH guidelines for laboratory animal housing and care and were approved by the IACUC of UNMC. Human monocytes were isolated by leukapheresis from HIV-1/2 and hepatitis seronegative donors and were deemed exempt from approval by the IRB of UNMC. Human CD34+ hematopoietic stem cells were isolated from umbilical cord blood, which is also exempt from UNMC IRB approval.

Author contributions
Conceptualization: DPG, HEG, and SG; methodology: DPG, PKD, BJS, ZL, ANB, DLP, NG, YA, JM, RLM, and BE; investigation: DPG, PKD, BJS, ZL, and ANB; writing of the original draft: DPG and HEG; review and editing of the manuscript: DPG, SG, HEG, JM, RLM, and HAG; funding acquisition: HEG, SG, and HAG; and supervision: PKD, HEG, and SG.

Acknowledgments
We thank Edward Makarov, Li Wu, Hang Su, Pavan Puligujja, James Hilaire, Amy Conaway, and Jenna M. Puccini for their technical assistance and Larisa Poluektova for lively discussions. We thank Myron Toews for critical comments on the manuscript and Jane Meza for statistical analysis. (All of the above-named individuals are from the University of Nebraska Medical Center.) We also thank the members of the UNMC confocal, elutriation, and animal facilities for their experimental support. This work was supported in part by the University of Nebraska Foundation, which includes donations from the Carol Swarts, MD, Emerging Neuroscience Research Laboratory; the Margaret R. Larson Professorship; the Frances and Louie Blumkin Foundation; the Harriet Singer Endowment and the Vice Chancellor’s Office of UNMC for Core Facility Development. We acknowledge support from NIH grants ROI MH04147, P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261, P30 AI078498, and R01 AG043540. ViiV Healthcare provided grant support for the development of long-acting antiretroviral drugs. BE is a ViiV Healthcare Scholar.

Address correspondence to: Santhi Gorantla or Howard E. Gendelman, Department of Pharmacology and Experimental Neuroscience 985880, University of Nebraska Medical Center, Omaha Nebraska 68198-5880, USA. Phone: 402.559.8754; E-mail: sgorantla@unmc.edu (S. Gorantla). Phone: 402.559.8920; E-mail: hegendel@unmc.edu (H.E. Gendelman).


